Antibiotic treatment in cystic fibrosis: Part 1: Introduction: Clinical pharmacokinetics and toxicology

Daniël J. Touw; Johan W. Mouton; Alexander A.T.M.M. Vinks; Alphons M. Horrevorts; Harry G.M. Heijerman

doi:10.1016/S1069-417X(00)89003-2

Antibiotic treatment in cystic fibrosis: Part 1: Introduction: Clinical pharmacokinetics and toxicology

Daniël J. Touw, Johan W. Mouton^*, Alexander A.T.M.M. Vinks, Alphons M. Horrevorts, Harry G.M. Heijerman

^*Corresponding author voor dit werk

Onderzoeksoutput › Professional

1 Citaat (Scopus)

Originele taal-2	English
Pagina's (van-tot)	25-29
Aantal pagina's	5
Tijdschrift	Antimicrobics and Infectious Diseases Newsletter
Volume	18
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1016/S1069-417X(00)89003-2
Status	Published - apr.-2000

Toegang tot document

10.1016/S1069-417X(00)89003-2

Handle.net

Permanente koppeling

Document onder embargo

Antibiotic treatment in cystic fibrosis Part 1
Final publisher's version, 777 KB
Kopie aanvragen

Citeer dit

@article{bf98fce8090744289d33675480185512,

title = "Antibiotic treatment in cystic fibrosis: Part 1: Introduction: Clinical pharmacokinetics and toxicology",

keywords = "aminoglycoside, aminoglycoside antibiotic agent, amoxicillin plus clavulanic acid, beta lactam antibiotic, colistin, cotrimoxazole, doxycycline, flucloxacillin, fusidic acid, macrolide, pheneticillin, quinoline derived antiinfective agent, quinolone, rifampicin, chronicity, clinical feature, cystic fibrosis, dose calculation, drug bioavailability, drug clearance, drug distribution, drug indication, drug metabolism, genotype, Haemophilus influenzae, human, infection prevention, maintenance therapy, Pseudomonas aeruginosa, respiratory tract infection, review, Staphylococcus aureus, survival rate, treatment indication",

author = "Touw, {Dani{\"e}l J.} and Mouton, {Johan W.} and Vinks, {Alexander A.T.M.M.} and Horrevorts, {Alphons M.} and Heijerman, {Harry G.M.}",

year = "2000",

month = apr,

doi = "10.1016/S1069-417X(00)89003-2",

language = "English",

volume = "18",

pages = "25--29",

journal = "Antimicrobics and Infectious Diseases Newsletter",

issn = "1069-417X",

number = "4",

}

TY - JOUR

T1 - Antibiotic treatment in cystic fibrosis: Part 1

T2 - Introduction: Clinical pharmacokinetics and toxicology

AU - Touw, Daniël J.

AU - Mouton, Johan W.

AU - Vinks, Alexander A.T.M.M.

AU - Horrevorts, Alphons M.

AU - Heijerman, Harry G.M.

PY - 2000/4

Y1 - 2000/4

KW - aminoglycoside

KW - aminoglycoside antibiotic agent

KW - amoxicillin plus clavulanic acid

KW - beta lactam antibiotic

KW - colistin

KW - cotrimoxazole

KW - doxycycline

KW - flucloxacillin

KW - fusidic acid

KW - macrolide

KW - pheneticillin

KW - quinoline derived antiinfective agent

KW - quinolone

KW - rifampicin

KW - chronicity

KW - clinical feature

KW - cystic fibrosis

KW - dose calculation

KW - drug bioavailability

KW - drug clearance

KW - drug distribution

KW - drug indication

KW - drug metabolism

KW - genotype

KW - Haemophilus influenzae

KW - human

KW - infection prevention

KW - maintenance therapy

KW - Pseudomonas aeruginosa

KW - respiratory tract infection

KW - review

KW - Staphylococcus aureus

KW - survival rate

KW - treatment indication

U2 - 10.1016/S1069-417X(00)89003-2

DO - 10.1016/S1069-417X(00)89003-2

M3 - Book/Film/Article review

SN - 1069-417X

VL - 18

SP - 25

EP - 29

JO - Antimicrobics and Infectious Diseases Newsletter

JF - Antimicrobics and Infectious Diseases Newsletter

IS - 4

ER -